Mode
Text Size
Log in / Sign up

Spondyloarthritis

Part of Arthritis

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Spondyloarthritis

8 trials tracked for Spondyloarthritis: 7 in phase 3 or 4 and 6 with published results. The most-cited published study has 15 citations.

8Trials tracked
7Phase 3 & 4
0Recruiting
6With published results
Phase distribution
Phase 4 2 Phase 3 5 Other / NA 1
  1. Phase 3 A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis Completed · 15 cited
  2. Phase 3 A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis Completed · 14 cited
  3. Phase 4 Golimumab (MK-8259 / SCH900259) Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (GO-BACK) (MK-8259-038) Completed · 10 cited
  4. Phase 3 SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritis Completed · 8 cited
  5. Phase 3 A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis Completed · 6 cited
  6. Phase 3 A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis Completed · 5 cited
Show 2 more trials
  1. Phase 4 Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing Completed
  2. N/A Imaging Biomarkers in Crohn's Associated Spondyloarthritis Completed

Showing the 8 most-cited and recently-updated of 8 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Arthritis

Related studies from across the Arthritis family.

Long-term personalized exercise therapy shows potential cost-effectiveness for patients with axial spondyloarthritis
Rheumatology RCT
Long-term personalized exercise therapy shows potential cost-effectiveness for patients with axial spondyloarthritis Personalized exercise therapy shows promise for axial spondyloarthritis patients
Researchers evaluated the cost-utility of long-term, personalized exercise therapy compared to usual care in patients with axial spondyloart…
New research looks at whether personalized, long-term exercise programs are a cost-effective way to manage severe axial spondyloarthritis.
Biologic and targeted synthetic DMARDs show reassuring malignancy safety in inflammatory arthritides, but non-melanoma skin cancer risk rises with TNF inhibitors
Allergy & Immunology Sys. Review
Biologic and targeted synthetic DMARDs show reassuring malignancy safety in inflammatory arthritides, but non-melanoma skin cancer risk rises with TNF inhibitors Biologics for arthritis: Cancer risk appears low overall
This narrative review of biologic and targeted synthetic DMARDs in immune-mediated inflammatory arthritides finds most therapies have reassu…
Most biologic arthritis drugs don't raise overall cancer risk, but skin cancer risk may be higher with some.
Living systematic review finds low-certainty evidence that stopping csDMARDs before surgery may increase flare risk in inflammatory arthritis
Allergy & Immunology Sys. Review
Living systematic review finds low-certainty evidence that stopping csDMARDs before surgery may increase flare risk in inflammatory arthritis Stopping arthritis drugs before surgery may raise flare risk
This living systematic review evaluates perioperative management of conventional synthetic DMARDs in adults with rheumatoid arthritis, psori…
Low-certainty evidence suggests stopping certain arthritis drugs before surgery might increase the chance of a disease flare, but infection …
Vunakizumab improves ASAS20 response in active radiographic axial spondyloarthritis at 16 weeks
Rheumatology RCT
Vunakizumab improves ASAS20 response in active radiographic axial spondyloarthritis at 16 weeks New Drug Offers Hope for Ankylosing Spondylitis Patients
This randomized, double-blind, placebo-controlled phase 2 to 3 trial included 548 adults with active r-axSpA in China. At week 16, the vunak…
If you live with the daily stiffness and pain of ankylosing spondylitis, a new treatment option may be on the horizon that works better than…
Meta-analysis identifies genetic variants linked to inflammatory pathways in rheumatoid arthritis and axial spondyloarthritis
Rheumatology Meta-analysis
Meta-analysis identifies genetic variants linked to inflammatory pathways in rheumatoid arthritis and axial spondyloarthritis New Gene Links Found Between Two Major Joint Diseases
This meta-analysis synthesizes data from three large European cohorts to identify new overlapping and disease-specific genetic risk factors …
This study reveals how specific genes may drive both shared and unique features of two common joint diseases, opening doors for more persona…